The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...
Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...
Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...
GlobalData on MSN11d
Insulet rolls out iPhone app for Omnipod 5 insulin pump in USInsulet has launched the Omnipod 5 automated insulin delivery app for iPhone in the US. The app obviates the need for ...
PORTLAND, GA, UNITED STATES, November 5, 2024 /EINPresswire / -- The global Implantable Insulin Pump Market was pegged at $2.67 billion in 2020, and is estimated to reach $6.44 billion by 2030, ...
PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.
The rising popularity of the continuous glucose monitor, which is not the same as an insulin pump, has been a huge advance in ...
Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...
Luxembourg's Ministry of Health and Social Security has reported that a safety notice regarding certain models... }} ...
PharmaSens, a developer of innovative insulin patch pumps for people with diabetes, has announced the appointment of Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.
PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.
Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback